Paula Rojas García1, Simon van der Pol2, Antoinette D I van Asselt2,3, Maarten Postma2,4, Roberto Rodríguez-Ibeas1, Carmelo A Juárez-Castelló1, Marino González1, Fernando Antoñanzas1. 1. Department of Economics and Business, University of La Rioja, 26004 Logroño, Spain. 2. University Medical Center Groningen, Department of Health Sciences, University of Groningen, 9713 GZ Groningen, The Netherlands. 3. University Medical Center Groningen, Department of Epidemiology, University of Groningen, 9713 GZ Groningen, The Netherlands. 4. Department of Economics, Econometrics and Finance, University of Groningen, 9747 AE Groningen, The Netherlands.
Abstract
BACKGROUND: The most recommended treatment for a Helicobacter pylori infection is high doses of combined antibiotics. The objective of this article is to perform a systematic review of the economic evaluation studies applied to assess the efficiency of diagnostic testing for H. pylori infections, so that their main characteristics can be identified and to learn from the literature how the antimicrobial resistance (AMR) issue is incorporated into these economic evaluations. METHODS: We conducted a systematic review to compare the costs and clinical effectiveness of diagnostic strategies for H. pylori infections. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and extracted the items from the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. RESULTS: We found thirteen articles that were of good quality according to CHEERS: six studies focused on diagnostics of Helicobacter pylori infections associated with dyspepsia and four on duodenal ulcers. Testing was found to be the most cost-effective strategy in eight articles. Four studies considered AMR. CONCLUSIONS: Testing was more cost-effective than empirical treatment, except in cases of high prevalence (as with developing countries) or when patients could be stratified according to their comorbidities. The introduction of AMR into the model may change the efficiency of the testing strategy.
BACKGROUND: The most recommended treatment for a Helicobacter pyloriinfection is high doses of combined antibiotics. The objective of this article is to perform a systematic review of the economic evaluation studies applied to assess the efficiency of diagnostic testing for H. pylori infections, so that their main characteristics can be identified and to learn from the literature how the antimicrobial resistance (AMR) issue is incorporated into these economic evaluations. METHODS: We conducted a systematic review to compare the costs and clinical effectiveness of diagnostic strategies for H. pylori infections. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and extracted the items from the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. RESULTS: We found thirteen articles that were of good quality according to CHEERS: six studies focused on diagnostics of Helicobacter pylori infections associated with dyspepsia and four on duodenal ulcers. Testing was found to be the most cost-effective strategy in eight articles. Four studies considered AMR. CONCLUSIONS: Testing was more cost-effective than empirical treatment, except in cases of high prevalence (as with developing countries) or when patients could be stratified according to their comorbidities. The introduction of AMR into the model may change the efficiency of the testing strategy.
Authors: Ahmet Burak Toros; Ali Tüzün Ince; Besir Kesici; Mustafa Saglam; Zulfikar Polat; Ahmet Uygun Journal: Helicobacter Date: 2011-06 Impact factor: 5.753
Authors: Anna García-Altés; Rosa Rota; Mercè Barenys; Agueda Abad; Victor Moreno; Joan M V Pons; Josep M Piqué Journal: Eur J Gastroenterol Hepatol Date: 2005-07 Impact factor: 2.566
Authors: Francis Megraud; Samuel Coenen; Ann Versporten; Manfred Kist; Manuel Lopez-Brea; Alexander M Hirschl; Leif P Andersen; Herman Goossens; Youri Glupczynski Journal: Gut Date: 2012-05-12 Impact factor: 23.059
Authors: Simon van der Pol; Paula Rojas Garcia; Fernando Antoñanzas Villar; Maarten J Postma; Antoinette D I van Asselt Journal: Pharmacoeconomics Date: 2021-11-01 Impact factor: 4.981
Authors: Paula Rojas-Garcia; Simon van der Pol; Antoinette D I van Asselt; Maarten J Postma; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló; Marino González; Fernando Antoñanzas Journal: Antibiotics (Basel) Date: 2021-12-27